Marie Kosco-Vilbois

Dr. Kosco-Vilbois, a US citizen, has extensive experience in the biopharmaceutical industry and served as Chief Scientific Officer for AC Immune from 2019 to 2023, following her role as Chief Scientific Officer for Novimmune from 2005. Prior to joining Novimmune in 2002, Dr. Kosco-Vilbois was Head of Immunology and Preclinical Pharmacology at the Serono Pharmaceutical Research Institute, a Senior Scientist and then Head of Immunology at the Glaxo Wellcome Research Institute in Geneva and a Scientific Member of the Basel Institute for Immunology. During her career, she has taken numerous Biologicals from Discovery into pre-clinical studies and clinical development, most notably filing market applications of a Biological for an Orphan indication.   Dr. Kosco-Vilbois gained her Bachelor’s Degree in Biology from Rutgers University, New Jersey, US, and a Ph.D. in Anatomy and Immunology from the Medical College of Virginia/Virginia Commonwealth University School of Medicine, US.